Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Simon R. Johnson"'
Autor:
Debbie Clements, Suzanne Miller, Roya Babaei-Jadidi, Mike Adam, S. Steven Potter, Simon R. Johnson
Publikováno v:
American Journal of Physiology-Lung Cellular and Molecular Physiology. 322:L283-L293
Lymphangioleiomyomatosis (LAM) is a female-specific cystic lung disease in which tuberous sclerosis complex 2 (TSC2)-deficient LAM cells, LAM-associated fibroblasts (LAFs), and other cell types infiltrate the lungs. LAM lesions can be associated with
Autor:
Iain A. Stewart, Suzanne Miller, Debbie Clements, Irshad Soomro, Simon R. Johnson, Roya Babaei-Jadidi
Publikováno v:
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 215-226 (2020)
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 215-226 (2020)
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease with a variable clinical course. The lungs are infiltrated by nodules of LAM cells, stromal cells and inflammatory cells, causing lung cysts and respiratory failure. We used immunohistochem
Autor:
Roya Babaei-Jadidi, Marcos Castellanos Uribe, Suzanne Miller, Peter Bradding, Abdolrahman S. Nateri, Iain D Stewart, Debbie Clements, Zoe M Thompson, Sean T. May, Arundhati Dongre, Simon R. Johnson
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
Rationale: Lymphangioleiomyomatosis (LAM) is a multisystem disease that causes lung cysts and respiratory failure. Loss of TSC (tuberous sclerosis complex) gene function results in a clone of “LAM ...
Publikováno v:
The Lancet. Respiratory medicine. 9(11)
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low-grade, metastasising neoplasm of women, characterised by infiltration of the lung parenchyma with abnormal smooth muscle-like cells, resulting in cystic lung destruction. The invading cell i
Funder: Nottingham Molecular Pathology Node
Funder: NIHR Rare Diseases Translational Research Collaboration
Background: Lymphangioleiomyomatosis (LAM) is a rare multisystem disease almost exclusively affecting women which causes loss of lun
Funder: NIHR Rare Diseases Translational Research Collaboration
Background: Lymphangioleiomyomatosis (LAM) is a rare multisystem disease almost exclusively affecting women which causes loss of lun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c57dddbac3e27fe082cd5760992f137
https://www.repository.cam.ac.uk/handle/1810/306638
https://www.repository.cam.ac.uk/handle/1810/306638
Publikováno v:
Medical hypotheses. 141
Lymphangioleiomyomatosis (LAM) is a cystic lung disease mainly affecting women, in which degradation of the lung parenchyma is associated with a cell of unknown provenance, known as a LAM cell. LAM cells carry TSC2 mutations and can be identified in
Publikováno v:
Rare ILD/DPLD.
Introduction: LAM is a rare lung disease characterised by progressive cystic destruction of the lung. There is no effective treatment. The hallmark lesion of LAM is the LAM nodule, a complex structure consisting of proliferating smooth muscle-like
Publikováno v:
Signal failures: mechanisms of lung disease.
Introduction and objectives LAM is a rare, progressive interstitial lung disease characterised by progressive cystic destruction of the lung. There is currently no effective treatment for LAM. The hallmark lesion of LAM lung disease is the LAM nodule
Autor:
Kevin K. Brown, Yoshikazu Inoue, Karen Smith, Kevin C. Wilson, Angelo M. Taveira-Da Silva, Steven A. Sahn, Gregory P. Downey, Simon R. Johnson, Vincent Cottin, Kuniaki Seyama, Nishant Gupta, MeiLan K. Han, Jeffrey T. Chapman, Eugene J. Sullivan, Jan Brozek, Lisa R. Young, Elizabeth P. Henske, Jeanine D'Armiento, Joel Moss, Geraldine R. Finlay, John J. Bissler, Cristopher A. Meyer, Francis X. McCormack, Robert M. Kotloff, Wendy K. Steagall, Thomas V. Colby, Jay H. Ryu, Charlie Strange, Jean F. Cordier, Kathryn A. Wikenheiser-Brokamp, Brent W. Kinder, Connie G. Glasgow
Background: Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affects women. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of LAM.Methods: Systematic reviews were performed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3747eb67c592ce58b0178884bf638418
https://europepmc.org/articles/PMC5803656/
https://europepmc.org/articles/PMC5803656/
Publikováno v:
The Journal of Immunology. 185:1812-1821
Lymphangioleiomyomatosis (LAM) is a progressive disease caused by accumulation of metastatic (LAM) cells in the lungs, lymphatics, and the tumor angiomyolipoma (AML). LAM cells have biallelic loss of either tuberous sclerosis complex gene (but predom